Table 1 Summary of the results obtained for the tested 5-MeO-tryptamines, with their structure and physicochemical properties.

From: Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties

Compounds

5-MeO-DMT

5-MeO-MET

5-MeO-DET

5-MeO-pyr-T

5-MeO-MALT

5-MeO-DALT

5-MeO-NIPT

5-MeO-MIPT

5-MeO-EIPT

5-MeO-DIPT

Chemical structure

Molecular volume (Å3)

237.63

252.00

273.25

262.37

266.38

300.13

255.25

274.50

290.00

308.38

Octanol-water p. coefficient (logP)

2.33

2.71

3.08

2.73

2.97

3.62

2.76

3.00

3.38

3.68

5-HT1AR

Ki ± SD (nM)

2.57 ± 0.09

3.11 ± 0.51

4.93 ± 0.62

0.577 ± 0.195

5.96 ± 0.47

3.26 ± 0.39

15.7 ± 2.3

24.8 ± 7.6

18.4 ± 8.4

15.8 ± 1.3

5-HT2AR

Ki ± SD (nM)

105 ± 22

94.1 ± 16.7

128 ± 4

373 ± 59

52.9 ± 9

71.7 ± 14.8

123 ± 38

147 ± 32

151 ± 26

399 ± 49

SERT

Ki ± SD (nM)

14,510 ± 2925

7710 ± 3378

10,410 ± 970

3006 ± 354

4015 ± 417

1189 ± 96

8590 ± 1706

2869 ± 928

1776 ± 83

1618 ± 475

5-HT uptake inhibition

IC50 ± SD (nM)

50,068 ± 31,457

30,102 ± 12,585

60,012 ± 28,013

2765 ± 1431

44,053 ± 11,421

22,313 ± 4688

32,110 ± 11,497

29,768 ± 3918

22,172 ± 5870

24,215 ± 1977

5-HT2AR calcium mobilization

EC50 ± SD (nM);

Emax ± SD (%5-HT)

5.28 ± 1.87

100 ± 5

4.46 ± 0.06

102 ± 5

17.1 ± 5.1

102 ± 7

13.5 ± 2.2

92 ± 4

4.95 ± 0.47

99 ± 9

11.3 ± 3.3

99 ± 2

13.2 ± 3.6

91 ± 1

5.88 ± 2.39

96 ± 1

23.6 ± 1.6

103 ± 4

6.21 ± 1.25

99 ± 6

HTR

pED50 (ED50 mg/kg)

(95% CI pED50)

Emax (HTR events)

(95% CI)

0.685 (4.84)

(0.499–0.871)

38.1

(31.7–44.5)

0.435 (2.72)

(0.188–0.682)

28.4

(23.5–33.2)

0.365 (2.32)

(0.018–0.711)

9.73

(7.61–11.85)

0.863 (7.29)

(0.626–1.080)

10.0

(6.9–13.1)

−0.099 (0.796)

((−0.283)–0.085)

27.6

(23.2–32.0)

0.619 (4.16)

(0.419–0.818)

10.4

(8.5–12.4)

0.686 (4.85)

(0.154–1.217)

7.58

(5.46–9.71)

−0.102 (0.791)

((−0.344)–0.141)

14.19

(11.7–16.68)

1.03 (10.6)

(0.87–1.18)

9.27

(7.10–11.44)

−0.322 (0.477)

−(0.626–0.017)

10.5

(8.5–12.5)

Change in body temperature

pED50 (ED50 mg/kg)

(95% CI pED50)

Emax (ΔT ºC)

(95% CI)

0.677 (4.75)

(0.307–1.046)

−1.63

−(2.15–1.11)

0.678 (4.76)

(0.268–1.088)

−1.72

−(2.26–1.17)

0.856 (7.18)

(0.697–1.016)

−4.18

−(4.77–3.60)

0.461 (2.89)

(0.257–0.664)

−4.31

−(4.88–3.74)

1.01 (10.2)

(0.80–1.22)

−2.75

−(3.45–2.06)

1.13 (13.6)

(1.04–1.23)

−2.63

−(3.02–2.23)

0.867 (7.35)

(0.720–1.013)

−4.24

−(4.86–3.61)

1.17 (14.8)

(0.951–1.388)

−3.62

−(4.57–2.67)

1.18 (15.0)

(0.991–1.358)

−4.32

−(5.33–3.30)

1.17 (14.8)

(0.93–1.40)

−3.98

−(5.2–2.75)

HLA (hypolocomotion) pED50 (ED50 mg/kg) (95% CI)

−0.011 (0.976)

((−0.327)–0.305)

0.229 (1.70)

(0.094–0.364)

0.679 (4.78)

(0.216–1.142)

0.205 (1.60)

(0.011–0.399)

0.865 (7.32)

(0.529–1.201)

0.794 (6.22)

(0.533–1.055)

0.292 (1.96)

(0.161–0.422)

0.817 (6.57)

(0.568–1.067)

0.683 (4.82)

(0.466–0.900)

0.655 (4.52)

(0.314–0.997)

Emax (% reduction)

(95% CI)

41.72

(32.18–51.26)

66.79

(58.20–75.37)

63.56

(37.58–89.53)

71.25

(60.71–81.79)

85.40

(55.18–115.6)

73.11

(57.45–88.78)

77.64

(69.78–85.50)

82.78

(62.16–103.4)

68.02

(54.57–81.46)

55.32

(38.20–72.44)

  1. Titles and means in bold.
  2. In vitro results for 5-HT1AR, 5-HT2AR, SERT binding affinities, 5-HT2AR-mediated calcium mobilization (Emax and EC50) and 5-HT uptake inhibition (IC50). In vivo HTR studies, change in body temperature and HLA. In vitro results are presented as means ± SD for N ≥ 3. In vivo results (N = 8–10) are presented as Emax and pED50 with 95% CI. ED50 values are also shown (between parentheses) for clarity purposes.